Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články
PubMed
25503188
PII: 34/12/7461
Knihovny.cz E-zdroje
- Klíčová slova
- Hyponatremia, NSCLC, OS, PFS, predictive marker, prognosis,
- MeSH
- chinazoliny terapeutické užití MeSH
- dospělí MeSH
- erbB receptory antagonisté a inhibitory MeSH
- erlotinib MeSH
- hyponatremie krev diagnóza MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery krev MeSH
- nádory plic krev farmakoterapie mortalita MeSH
- nemalobuněčný karcinom plic krev farmakoterapie mortalita MeSH
- přežití bez známek nemoci MeSH
- proporcionální rizikové modely MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sodík krev MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- chinazoliny MeSH
- erbB receptory MeSH
- erlotinib MeSH
- inhibitory proteinkinas MeSH
- nádorové biomarkery MeSH
- sodík MeSH
BACKGROUND: Hyponatremia is a well-known phenomenon in cancer patients. The aim of our retrospective study was to assess the relationship of natremia levels to predict treatment with erlotinib and also to assess the prognosis of patients with hyponatremia. PATIENTS AND METODS: We analyzed data of 544 patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. RESULTS: Hyponatremia was measured in 21.5 % of patients before treatment with erlotinib. We found a significant increase in the effectiveness of treatment with erlotinib in patients with normal levels of sodium to hyponatremic patients. Progression-free survival (PFS) and overall survival (OS) were also significantly higher in patients with normal natremia. Multivariate Cox model analysis demonstrated that natremia was an independent factor for PFS and OS. CONSLUSION: We reported hyponatremia not only as a prognostic marker in NSCLC patients but also as predictive marker of erlotinib treatment efficacy, being an independent factor at the present large retrospective study. Its possible effect in clinical practice is bigger thanks the simple possibility of testing of hyponatremia and the low cost of this biomarker.
Centre for Applied Genomics of Solid Tumours Genomac Research Institute Prague Czech Republic
Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic
